SEATTLE, Oct. 12 /PRNewswire/ -- Corus Pharma, Inc., has added Dinu Sen to its senior management team and he will join the company as Chief Commercial Officer. Sen will report directly to the Company's Chief Executive Officer, A. Bruce Montgomery, MD.
Sen has extensive marketing and senior management experience in the biotech industry. Prior to joining Corus Pharma, Sen served as President and Chief Operating Officer at Cubist Pharmaceuticals; Senior Vice President of Marketing and Sales at PathoGenesis and Vice President of Sales and Marketing at Schwarz Pharma. Sen also held senior marketing positions at Amgen.
Over the past eighteen years, Sen has been involved in marketing some of the most successful brands in biotechnology, including Epogen(R), Neupogen(R) and TOBI(R). At Schwarz Pharma, he was a member of the team that in licensed Verelan PM(R), a calcium channel blocker used to treat high blood pressure. He subsequently led the team that launched the product. He has experience in initiating Phase IV clinical studies to support brand expansion, and has built management teams with marketing, sales, clinical, licensing and development expertise.
Sen received a Masters in Management and a concentration in Marketing, Finance and Health Care from Kellogg Graduate School of Business, Northwestern University. He was a Fellow of The Institute of Chartered Accountants of England and Wales, and received a Bachelor of Arts from St. Stephen's College, University of Delhi.
"Dinu is a great addition to the Corus management team as we seek to advance our pipeline and build our brands," said A. Bruce Montgomery, MD, Chief Executive Officer of Corus Pharma. "Having worked with him at PathoGenesis, I know personally what he brings to the table and believe his expertise will be invaluable as we seek to take our respiratory medicines to market."
About Corus Pharma:
Corus Pharma is committed to developing and commercializing products that help provide improved health and superior quality of life for patients with severe respiratory and infectious diseases. More information about Corus Pharma may be found at http://www.coruspharma.com/.
Corus Pharma, Inc.
CONTACT: Jonathan Mow of Corus Pharma, +1-206-792-3020; or Leslie Cohanof Dave Syferd & Partners, +1-206-262-0395, or email@example.com, for CorusPharma